VetDC Receives FDA Conditional Approval of TANOVEA®-CA1, the First New Animal Drug for Treating Lymphoma in Dogs

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., a veterinary cancer therapeutics company, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) has granted a conditional approval of TANOVEA®-CA1 (rabacfosadine for injection) for the treatment of lymphoma in … Keep Reading